Sandoz Group AG (SWX:SDZ)
47.67
+0.33 (0.70%)
Sep 19, 2025, 5:31 PM CET
Sandoz Group AG Revenue
Sandoz Group AG had revenue of $5.27B USD in the half year ending June 30, 2025, with 6.80% growth. This brings the company's revenue in the last twelve months to $10.59B, up 4.71% year-over-year. In the year 2024, Sandoz Group AG had annual revenue of $10.38B with 4.06% growth.
Revenue (ttm)
$10.59B
Revenue Growth
+4.71%
P/S Ratio
2.44
Revenue / Employee
$480.16K
Employees
22,049
Market Cap
20.53B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.38B | 405.00M | 4.06% |
Dec 31, 2023 | 9.98B | 673.00M | 7.23% |
Dec 31, 2022 | 9.31B | -372.00M | -3.84% |
Dec 31, 2021 | 9.68B | 20.00M | 0.21% |
Dec 31, 2020 | 9.66B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 63.49B |
Novartis AG | 43.89B |
Lonza Group AG | 7.09B |
Galderma Group AG | 3.73B |
Alcon | 7.97B |
Straumann Holding AG | 2.58B |
Sonova Holding AG | 3.87B |
Ypsomed Holding AG | 748.87M |
Sandoz Group AG News
- 11 days ago - Regeneron (REGN) Reaches Settlement with Sandoz Over Eylea Biosimilar - GuruFocus
- 24 days ago - Sandoz welcomes Quebec government support for Boucherville plant modernization project - Benzinga
- 5 weeks ago - Lupin partners with Sandoz to commercialize Ranibizumab biosimilar in multiple global markets - Business Upturn
- 6 weeks ago - Sandoz Group AG 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 6 weeks ago - Sandoz Group AG (SDZNY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee - Fortune
- 3 months ago - Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor - Benzinga
- 5 months ago - Sandoz Group AG (SDZNY) Q1 2025 Earnings Call Transcript - Seeking Alpha